Meir Preis

Hematology

1 Medical Center Dr
Lebanon, NH 03756

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

Journal: The New England journal of medicine

Published: May 29, 2026

The Use of Point-of-Care Hemoglobin Measurements in an Elderly Population with Hematological Disorders and Anemia.

The Use of Point-of-Care Hemoglobin Measurements in an Elderly Population with Hematological Disorders and Anemia.

Journal: Hematology reports

Published: March 29, 2026

Autosomal dominant thrombocytopenia associated with the CYCS p.Arg92Gly variant: clinical characterization of an additional family and observation of antiplatelet tolerance.

Autosomal dominant thrombocytopenia associated with the CYCS p.Arg92Gly variant: clinical characterization of an additional family and observation of antiplatelet tolerance.

Journal: Platelets

Published: February 12, 2026

ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study.

ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study.

Journal: Haematologica

Published: August 19, 2025

Role of a Designated Pharmacist in Reducing Adverse Drug Reaction Rates and Preventing Potential Medication Errors in Hematology-Oncology: A Randomized Controlled Trial.

Role of a Designated Pharmacist in Reducing Adverse Drug Reaction Rates and Preventing Potential Medication Errors in Hematology-Oncology: A Randomized Controlled Trial.

Journal: JCO oncology practice

Published: August 01, 2025

Efficacy and safety of direct oral anticoagulants in patients with venous thrombosis and inherited thrombophilia.

Efficacy and safety of direct oral anticoagulants in patients with venous thrombosis and inherited thrombophilia.

Journal: International journal of medical sciences

Published: December 05, 2024

Daratumumab and Romiplostim Combined Therapy for a Long-Standing Refractory Primary Immune Thrombocytopenia - Case Report.

Daratumumab and Romiplostim Combined Therapy for a Long-Standing Refractory Primary Immune Thrombocytopenia - Case Report.

Journal: ImmunoTargets and therapy

Published: August 17, 2024

Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional Study.

Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional Study.

Journal: Transplantation and cellular therapy

Published: July 31, 2024

Risk of Major Bleeding with Antiplatelet and/or Anticoagulation Therapy in Inherited Factor XI Deficiency: Insights from Real-World Observations.

Risk of Major Bleeding with Antiplatelet and/or Anticoagulation Therapy in Inherited Factor XI Deficiency: Insights from Real-World Observations.

Journal: Thrombosis and haemostasis

Published: June 18, 2024

Assessing the correlation between patient and family reported outcome measures and multiple myeloma clinical parameters.

Assessing the correlation between patient and family reported outcome measures and multiple myeloma clinical parameters.

Journal: Scientific reports

Published: May 14, 2024

Assessing the Impact of a Designated Pharmacist Intervention on Drug Treatment Costs and Technical Efficiency in the Hemato-Oncology Outpatient Clinic.

Assessing the Impact of a Designated Pharmacist Intervention on Drug Treatment Costs and Technical Efficiency in the Hemato-Oncology Outpatient Clinic.

Journal: Value in health regional issues

Published: December 19, 2023

Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes.

Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes.

Journal: Leukemia research

Published: July 06, 2023

Showing 1-12 of 35

Last Updated: 09/26/2026